Erythroplasia of Queyrat
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Synonyms and keywords: EQ
Overview
Historical Perspective
- Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin.
Pathophysiology
- The pathogenesis of Erythroplasia of Queyrat is characterized by squamous cell carcinoma in situ of the glans penis[1]
microscopic h*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway
Epidemiology and Demographics
Age
- Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old.
Gender
- Males areaffected with Erythroplasia of Queyrat.
Risk Factors
- Most common risk factor in the development of Erythroplasia of Queyrat are uncircumcised penis.
Diagnosis
Symptoms
- Symptoms of Erythroplasia of Queyrat may include the following:
- Red rash on the tip of the penis
- Irritation on the tip of the penis
Imaging Findings
- There are no imaging study findings associated with Erythroplasia of Queyrat.
Treatment
Medical Therapy
- The mainstay of therapy for Erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months.
Surgery
- Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat.
References
- ↑ Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of Dermatology (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.